Overcoming Challenges in AAV and LV Viral Vector Manufacturing: How To Design and Launch a Successful Clinical Materials Program

Gene & immune therapies have become increasingly important as they have the potential to treat and cure challenging diseases, such as cancer.

At IDT Biologika, we specialize in the contract development and manufacturing of virus-based vaccines and gene & immune therapies. Our team has extensive experience in the development and production of viral vectors, particularly in the use of Adeno-Associated Virus (AAV) platforms and also provide own cell lines for manufacturing. We are prepared to help you to overcome challenges in the process development and manufacturing of your AAV and LVV products.

Did you also know that IDT Biologika has already manufactured one of the first FDA and EMA approved commercial oncolytic products?

Read more about how IDT Biologika's expertise and experience can best serve your projects.

Register or Login and hit Download Now to get the full Special Report.